Mylan Company Profile (NASDAQ:MYL)

About Mylan

Mylan logoMylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MYL
  • CUSIP: 62853010
Key Metrics:
  • Previous Close: $38.12
  • 50 Day Moving Average: $43.20
  • 200 Day Moving Average: $44.54
  • 52-Week Range: $37.59 - $55.51
  • Trailing P/E Ratio: 24.13
  • Foreward P/E Ratio: 6.62
  • P/E Growth: 0.59
  • Market Cap: $20.39B
  • Outstanding Shares: 534,911,000
  • Beta: 1.25
  • Net Margins: 8.11%
  • Return on Equity: 23.22%
  • Return on Assets: 9.82%
  • Debt-to-Equity Ratio: 1.24%
  • Current Ratio: 3.23%
  • Quick Ratio: 2.65%
Additional Links:
Companies Related to Mylan:

Analyst Ratings

Consensus Ratings for Mylan (NASDAQ:MYL) (?)
Ratings Breakdown: 8 Hold Ratings, 8 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.59)
Consensus Price Target: $55.07 (44.46% upside)

Analysts' Ratings History for Mylan (NASDAQ:MYL)
DateFirmActionRatingPrice TargetDetails
9/22/2016Leerink SwannReiterated RatingBuyView Rating Details
9/22/2016ArgusSet Price TargetBuy$55.00View Rating Details
9/23/2016Sanford C. BernsteinSet Price TargetBuy$60.00View Rating Details
9/23/2016Deutsche Bank AGSet Price TargetBuy$60.00 -> $58.00View Rating Details
9/6/2016RBC Capital MarketsLower Price TargetSector Perform$52.00 -> $48.00View Rating Details
9/6/2016Royal Bank Of CanadaLower Price TargetSector Perform$52.00 -> $48.00View Rating Details
9/4/2016Wells Fargo & Co.Set Price TargetHold$44.00View Rating Details
8/30/2016BTIG ResearchReiterated RatingBuy$60.00View Rating Details
8/26/2016Evercore ISIReiterated RatingHold$49.00View Rating Details
8/25/2016Goldman Sachs Group Inc.Reiterated RatingConviction-Buy$60.00View Rating Details
8/24/2016Bank of America Corp.Reiterated RatingBuy$70.00View Rating Details
7/12/2016Morgan StanleyReiterated RatingHoldView Rating Details
6/25/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details
2/11/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
2/11/2016GuggenheimReiterated RatingNeutralView Rating Details
2/11/2016Cowen and CompanyLower Price TargetMarket Perform$65.00 -> $55.00View Rating Details
11/16/2015BMO Capital MarketsLower Price TargetMarket Perform$46.00View Rating Details
9/21/2015Barclays PLCInitiated CoverageEqual Weight$57.00View Rating Details
8/26/2015Standpoint ResearchInitiated CoverageBuy$70.00View Rating Details
8/12/2015SusquehannaLower Price TargetPositive$85.00 -> $68.00View Rating Details
6/18/2015B. RileyInitiated CoverageBuy$85.00 -> $71.23View Rating Details
6/3/2015Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
4/22/2015CRT CapitalBoost Price TargetBuy$68.00 -> $87.00View Rating Details
10/6/2014S&P Equity ResearchReiterated RatingBuyView Rating Details
10/6/2014ING GroupReiterated RatingBuy$68.00View Rating Details
(Data available from 9/30/2014 forward)


Earnings History for Mylan (NASDAQ:MYL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.69$0.70$1.87 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.73$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.68$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mylan (NASDAQ:MYL)
Current Year EPS Consensus Estimate: $4.96 EPS
Next Year EPS Consensus Estimate: $5.76 EPS


Dividend History for Mylan (NASDAQ:MYL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Mylan (NASDAQ:MYL)
Insider Ownership Percentage: 0.71%
Institutional Ownership Percentage: 60.20%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.50View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.30View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.00View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.00View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.80View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.32View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.00View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.10View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.21View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.04View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.00View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.00View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.50View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.00View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.95View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.00View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.32View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Mylan (NASDAQ:MYL)
News IconWhy congressional hearings still matter (NASDAQ:MYL) - September 30 at 6:25 PM
News IconWhy the $600 EpiPen costs $69 in Britain (NASDAQ:MYL) - September 30 at 6:25 PM logoMylan loses appeal of product-hopping case over acne drug (NASDAQ:MYL) - September 30 at 11:34 AM
News IconMylan and NextEra slump; ConAgra, Helmerich & Payne rise (NASDAQ:MYL) - September 30 at 11:34 AM
News IconFeds go after Mylan for scamming Medicaid out of millions on EpiPen pricing (NASDAQ:MYL) - September 30 at 11:34 AM logoBiotech beatdown: 2 trades (NASDAQ:MYL) - September 30 at 11:34 AM logoBiotech beatdown (NASDAQ:MYL) - September 30 at 11:34 AM logoMylan Launches Generic Fortamet® Tablets (NASDAQ:MYL) - September 30 at 11:34 AM logo9:51 am Mylan N.V. announces the U.S. launch of Metformin Hydrochloride Extended-release Tablets USP, 500 mg and 1000 mg, a generic version of Watson's (AGN (NASDAQ:MYL) - September 30 at 11:34 AM
News IconStock Tracker: Earnings & Estimates for Mylan Inc. (NASDAQ:MYL) - Frisco Fastball (NASDAQ:MYL) - September 29 at 6:17 PM logoMylan: Would A Generic Version Of EpiPen Affect Its Revenue? - Seeking Alpha (NASDAQ:MYL) - September 29 at 11:25 AM logoDid landmark laws from Congress enable high drug prices? (NASDAQ:MYL) - September 29 at 11:25 AM logoThe EpiPen costs 88% less in the UK than in the US (NASDAQ:MYL) - September 29 at 11:25 AM logoMylan Antitrust Suit Over Acne Drug Popped By 3rd Circ. (NASDAQ:MYL) - September 28 at 6:01 PM logoUPDATE 1-U.S. senators ask Justice Dept to consider probe of EpiPen Medicaid classification (NASDAQ:MYL) - September 28 at 6:01 PM
News IconU.S. Senator Prods Mylan on EpiPen 'Pay for Delay' Concerns (NASDAQ:MYL) - September 28 at 6:01 PM logoSenators ask Justice Department to investigate EpiPen maker (NASDAQ:MYL) - September 28 at 6:01 PM logoU.S. senators ask Justice Dept to consider probe of EpiPen Medicaid classification (NASDAQ:MYL) - September 28 at 6:01 PM logoA Modest Proposal To Reduce The Price of EpiPens (NASDAQ:MYL) - September 28 at 6:01 PM logoU.S. agency says it advised Mylan that EpiPen was misclassified (NASDAQ:MYL) - September 28 at 6:01 PM logoETF’s with exposure to Mylan NV : September 28, 2016 (NASDAQ:MYL) - September 28 at 11:19 AM logoSenators ask Justice Dept to consider probe of EpiPen Medicaid classification (NASDAQ:MYL) - September 28 at 11:19 AM logoSenators urge Department of Justice to investigate Mylan over EpiPen (NASDAQ:MYL) - September 28 at 11:19 AM logoMylan, Lupin said to weigh bids for Bayer dermatology business (NASDAQ:MYL) - September 27 at 6:11 PM logoMylan, Lupin Said to Weigh Bids for Bayer Dermatology Unit (NASDAQ:MYL) - September 27 at 6:11 PM logoScandal-Plagued Mylan NV's (MYL) Potential M&A Play (NASDAQ:MYL) - September 27 at 6:11 PM
News IconMylan CEO misled lawmakers about EpiPen profits—they’re 66% higher (NASDAQ:MYL) - September 27 at 6:11 PM logoMylan faces scrutiny over EpiPen profit data shown to Congress (NASDAQ:MYL) - September 27 at 6:11 PM logoDrug Price Bubble A Result Of Decade-Long Economic Policy Issues (NASDAQ:MYL) - September 27 at 6:11 PM logoMylan NV (MYL) Scandal Taking Down the Generic Drug Sector (NASDAQ:MYL) - September 27 at 11:03 AM logoMylan Inc. (NASDAQ:MYL) Mean Price Target At $55.857 - (NASDAQ:MYL) - September 27 at 10:53 AM
News IconMylan CEO misled lawmakers about EpiPen profits—they're 66% higher - Ars Technica (NASDAQ:MYL) - September 27 at 10:53 AM logoBill George on drug pricing: I want a market-based soluti... (NASDAQ:MYL) - September 27 at 10:53 AM logo3 Stocks to Watch Tuesday: Kite Pharma Inc (KITE), Array Biopharma Inc (ARRY) and Mylan NV (MYL) (NASDAQ:MYL) - September 27 at 9:21 AM logoAllergan (AGN), Mylan (MYL) Sees Short Interest Rise, Gilead (GILD) Fall in Pharma Sector - Guggenheim - (NASDAQ:MYL) - September 26 at 6:19 PM logo2 Takeaways From The Mylan Congressional EpiPen Hearing - Seeking Alpha (NASDAQ:MYL) - September 26 at 6:19 PM logoKite Pharma gets good news on lymphoma treatment (NASDAQ:MYL) - September 26 at 6:19 PM logoRep. Cummings: Don't believe Mylan's numbers this year (NASDAQ:MYL) - September 26 at 6:19 PM logoMylan (MYL) Accounted for a U.S. Tax Rate in the Profitability of the EpiPen. (NASDAQ:MYL) - September 26 at 6:19 PM logoEpipen's Profits Are Actually A Lot Higher Than Mylan Originally Told Congress (NASDAQ:MYL) - September 26 at 12:56 PM logoMylan's EpiPen Profit 60% Higher Than Told to Congress - Wall Street Journal (NASDAQ:MYL) - September 26 at 12:56 PM
News IconCongress Absolutely Unloads On Epipen CEO (NASDAQ:MYL) - September 26 at 11:01 AM logoPfizer says not to split into two (NASDAQ:MYL) - September 26 at 11:01 AM logoAnd Then There’s Mylan’s Specialty Segment, Home of the EpiPen (NASDAQ:MYL) - September 26 at 11:01 AM logoTeva Pharmaceutical Leads in Global Generic Pharmaceutical Space (NASDAQ:MYL) - September 26 at 11:01 AM
News IconMylan Inc. CEO Heather Bresch Testifies on EpiPen Price Increases (NASDAQ:MYL) - September 25 at 5:40 PM logoGenerics or Specialty: Which Mylan Segment Is Growing Fastest? (NASDAQ:MYL) - September 24 at 10:43 AM logo[$$] How Mylan Got the Market And Criticism It Deserves (NASDAQ:MYL) - September 24 at 10:43 AM
News IconMylan CEO Bresch’s pay irks lawmakers, investors (NASDAQ:MYL) - September 23 at 5:53 PM
News IconMylan CEO defends EpiPen cost to angry lawmakers (NASDAQ:MYL) - September 23 at 5:53 PM


Mylan (NASDAQ:MYL) Chart for Friday, September, 30, 2016

Last Updated on 9/30/2016 by Staff